ARS Pharmaceuticals, Inc.
Company Stats
- Market Cap
- $428.6M
- as of Sep 30, 2026
- Shares Outstanding
- 99.4M
- Free Float
- 45.7%
Income Statement
- Revenue
- $84.3M
- Operating Income
- -$179.4M
- Net Income
- -$171.3M
- EBITDA
- -$178.1M
- Revenue Growth, 3Y
- 300.1%
- FCF Margin, 3Y Avg
- -66108.4%
- FCF Margin, Worst Year
- -198136.7%
Cash Flow
- Free Cash Flow
- -$171.2M
- FCF Yield
- -39.9%
- Owner FCF Yield
- -45.1%
Balance Sheet
- Cash & Equivalents
- $41.3M
Returns & Capital
- SBC, 3Y Avg
- $15.3M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2025 | $84.3M | -$171.2M | -203.1% |
| FY2024 | $89.1M | $13.0M | 14.6% |
| FY2023 | $30,000 | -$59.4M | -198136.7% |
| FY2022 | $1.3M | -$40.3M | -3060.6% |
| FY2021 | $5.5M | -$17.6M | -319.9% |
Annual filing data through FY ended December 31, 2025; shares and float as of November 3, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges
Input Costs Squeeze Margins Even as Demand Holds Firm